Want to see GRCE full AI Analyst Report?
GRCE Stock Chart & Stats
$4.60
-$0.02(-0.47%)
At close: 4:00 PM EST
$4.60
-$0.02(-0.47%)
Day’s Range― - ―
52-Week Range$1.79 - $5.18
Previous CloseN/A
Volume30.96K
Average Volume (3M)58.56K
Market Cap
$36.45M
Enterprise Value$15.68M
Total Cash (Recent Filing)$16.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding16,274,027
10 Day Avg. Volume55,886
30 Day Avg. Volume58,559
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.20
Price to Sales (P/S)0.00
P/FCF Ratio-8.62
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.84K
Enterprise Value/Ebitda-1.21
Forecast
1Y Price Target
$6.00Price Target Upside30.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$5.00M
Bulls Say, Bears Say
Bulls Say
Phase 3 EfficacyA successful pivotal Phase 3 reduces clinical development risk and supports the product’s therapeutic rationale versus oral nimodipine. Durable clinical evidence increases the likelihood of physician adoption, reimbursement discussions, and lasting market penetration in a rare, high‑need indication once approved.
Orphan Status And IP ProtectionsOrphan designation and layered IP create structural commercial advantages: potential exclusivity, pricing flexibility, and higher entry barriers for competitors. These durable protections can enhance long‑term revenue potential and strategic partnerships once regulatory approval is secured.
Conservative Balance SheetMinimal debt reduces refinancing and interest burden, giving the company flexibility to fund NDA remediation and commercialization activities. Combined with meaningful equity and improving operating cash flow trends, the capital structure is a durable strength versus highly leveraged peers.
Bears Say
Pre-revenue CompanyNo commercial revenue over multiple years means the company remains entirely dependent on external funding and milestone-based financing. This structural absence of product cash flow prevents internal funding of growth, limits operating leverage, and maintains execution risk until launch.
Regulatory CMC And Manufacturing RiskA CRL focused on CMC, leachables and contract manufacturer deficiencies imposes a durable timeline and cost risk: additional studies, facility remediation and potential reinspection can materially delay approval and raise development costs even with no new clinical data requested.
Weak Cash Generation And Slim Internal BenchSustained negative operating cash flow combined with a very small employee base indicates reliance on external partners and capital. This structural constraint can slow remediation, scale-up, and commercialization efforts and heighten dilution risk as additional funding is required.
Grace Therapeutics News
GRCE FAQ
What was Grace Therapeutics’s price range in the past 12 months?
Grace Therapeutics lowest stock price was $1.79 and its highest was $5.18 in the past 12 months.
What is Grace Therapeutics’s market cap?
Grace Therapeutics’s market cap is $36.45M.
When is Grace Therapeutics’s upcoming earnings report date?
Grace Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.
How were Grace Therapeutics’s earnings last quarter?
Grace Therapeutics released its earnings results on Jun 18, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.23 by $0.17.
Is Grace Therapeutics overvalued?
According to Wall Street analysts Grace Therapeutics’s price is currently Undervalued.
Does Grace Therapeutics pay dividends?
Grace Therapeutics does not currently pay dividends.
What is Grace Therapeutics’s EPS estimate?
Grace Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Grace Therapeutics have?
Grace Therapeutics has 16,274,027 shares outstanding.
What happened to Grace Therapeutics’s price movement after its last earnings report?
Grace Therapeutics reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.23. Following the earnings report the stock price went up 7.207%.
Which hedge fund is a major shareholder of Grace Therapeutics?
Currently, no hedge funds are holding shares in GRCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grace Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (30.43% Upside)
$6.00 (30.43% Upside)
Crowd Wisdom
Positive
Last 7 Days ▲ 6.5%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.10%
12-Months-Change
Fundamentals
Return on Equity
-12.66%
Trailing 12-Months
Asset Growth
-4.48%
Trailing 12-Months
Company Description
Grace Therapeutics
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
GRCE Stock 12 Month Forecast
Average Price Target
$6.00
▲(30.43% Upside)
Technical Analysis
Ownership Overview
8.06%
Insiders
2.50% Mutual Funds
10.90% Other Institutional Investors
75.86% Public Companies and
Individual Investors